Cantor sets USD 8.00 target for Lexicon Pharmaceuticals stock

Published on 10/14/2026 at 05:37 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Average target rose to USD 4.64 from USD 3.93 on October 2, 2026. For Lexicon Pharmaceuticals stock, first-quarter 2027 data is next.

Clinical milestones shape valuation

On September 28, 2026, Cantor Fitzgerald initiated coverage with an USD 8.00 target.
Revenue was USD 0.7 million in the second quarter of 2026 versus USD 28.9 million.
Lexicon Pharmaceuticals had a USD 715.2 million market capitalization on October 13, 2026.

LXRX, US5288723027, Illustration mit AI erstellt.

Lexicon Pharmaceuticals (ISIN US5288723027) received an USD 8.00 price target from Cantor Fitzgerald when the firm initiated coverage on September 28, 2026, according to Nasdaq. The target gives the analyst view a clear clinical milestone to track, with first-quarter 2027 data from the SONATA-HCM study ahead.

Three milestones define the setup

On August 6, 2026, Lexicon reported second-quarter revenue of USD 0.7 million, down from USD 28.9 million in the second quarter of 2025, alongside a USD 31.8 million net loss. Benzinga reported that the quarter included higher clinical-trial spending and a non-cash debt extinguishment loss.

On September 28, 2026, Cantor Fitzgerald initiated coverage with an Overweight rating and an USD 8.00 target, while the average analyst target later reached USD 4.64 from USD 3.93. Nasdaq said the average target was revised on October 2, 2026.

On October 13-14, 2026, Lexicon management was scheduled to meet with Cantor in San Francisco. Markets Insider reported that the meeting was hosted by Cantor.

What does the milestone mean?

The SONATA-HCM study is the main bridge between the current valuation debate and Lexicon's pipeline. Management said enrollment was completed with more than 500 patients, and top-line data are expected in the first quarter of 2027, according to Benzinga.

Regulatory dates remain important

Lexicon also anticipated a resubmission of its Zynquista application by the end of October 2026. The company expects the SONATA-HCM readout in the first quarter of 2027, making those two milestones the next major dates for the biotechnology pipeline.

Market value and upcoming dates

Lexicon Pharmaceuticals had a market capitalization of USD 715.2 million on October 13, 2026. Its 52-week range was USD 1.10 to USD 2.68 on that date, placing the valuation against a wide biotechnology trading range.